Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation issues that come along this expensive and complex technology and shows how stem cell therapies can be better included in healthcare systems around the world.
As Korea is typically a follower country in the pharmaceutical industry, having a strong generics market, the government was interested in building a new innovative technology like stem cell therapy from scratch on Korean soil
